Harnessing AI for Healthcare: A New Dawn for South Africa

By Sumona Bose

February 7, 2024

The Need for AI-Driven Healthcare Policy in South Africa

South Africa’s healthcare sector is on the brink of a transformative era, with artificial intelligence (AI) at its helm. However, the current policy frameworks are ill-equipped to foster innovation in this burgeoning field. Five key issues demand immediate attention: outdated legislation, data and algorithmic bias, workforce impact, liability dilemmas, and a dearth of AI system innovation. The establishment of a comprehensive national policy framework addressing these concerns is crucial for the safe, responsible, and regulated adoption of AI in healthcare.

The Innovation Gap: AI Patenting in South Africa

A closer look at the patenting activity within AI in South Africa reveals a stark reality. Despite the country being listed in over 9,000 AI patent applications between 2012 and 2021, only ten patents were filed from within South Africa. This disparity underscores the need for an enabling environment that promotes the development of complex cognitive and creative AI systems.

Public Sector Data: The Key to AI-Driven Healthcare

One of the significant hurdles to AI development in Africa is data availability and the costs associated with its acquisition. The National Digital Health Strategy for South Africa 2019 – 2024 identifies the development of a patient electronic health record as a key priority. This record system could provide a wealth of high-quality data to train AI systems, alleviating the significant investment and effort required to curate non-optimised data.

The concept of using public sector data to develop, train, and improve AI-enabled systems is not new. The Declaration of Cooperation on Artificial Intelligence, ratified by 25 European countries in 2018, saw member states agree to ensure better access to public sector data to fuel AI development.

However, access to sensitive health data raises privacy and security concerns. A robust legal framework or governance system is needed to encourage innovation while preserving patient privacy and security. A federated data system, where data do not leave the participating organisation but can be accessed by authorised individuals to train algorithms, could be the solution.

Conclusion

The establishment of a public sector data institution, alongside the proposed patient electronic record, could incentivise the development and deployment of AI for use in healthcare in South Africa. By providing developers with secure and safe access to health data, we can respect the rights to intellectual property and digital authenticity.

Reference url

Recent Posts

oral GLP-1 medication
    

Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron Succeeds in Phase 3

🌟 Ready for a breakthrough in diabetes management?

Eli Lilly’s oral GLP-1 medication, orforglipron, has completed a successful Phase 3 trial, showing remarkable efficacy in lowering A1C levels and promoting substantial weight loss. As the first oral small molecule GLP-1 receptor agonist, it offers a promising alternative to conventional injectable treatments, potentially improving patient adherence and access.

Dive into the details of this exciting development and what it means for the future of diabetes care!

#SyenzaNews #HealthTech #Innovation #Pharmaceuticals

pediatric thyroid cancer risk
    

Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from a California Study

🌟 Are we overlooking environmental risks in pediatric cancer?

Recent research highlights a troubling link between perinatal exposure to PM2.5 and outdoor artificial light and the increased risk of pediatric thyroid cancer. This pivotal study sheds light on how environmental factors play a critical role in childhood health, particularly among vulnerable populations.

Dive into this important discussion on how addressing these environmental exposures may reduce pediatric thyroid cancer and improve health outcomes for future generations.

#SyenzaNews #EnvironmentalHealth #HealthPolicy #Innovation

capivasertib cost-effectiveness
      

Capivasertib Cost-Effectiveness in Advanced Breast Cancer

💡What’s the strategy to bring capivasertib’s price within reach of breast cancer patients?

A recent study evaluates capivasertib, an AKT inhibitor, as a second-line treatment for advanced breast cancer, revealing that its costs significantly outweigh the added health benefits. The analysis indicates that to be cost-effective, a substantial reduction in its price is necessary.

Delve into the economic implications of this treatment and the pressing need for pricing reforms in healthcare.

#SyenzaNews #HealthEconomics #costeffectiveness #oncology

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.